Navigation Links
MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,,Australia

nt manufacturing processes. The developed manufacturing methodology uses MaxCyte's proprietary platform technologies that have been described in a Master File with CBER, United States FDA and been cross- referenced in multiple clinical studies, and Medinet's technology and know-how derived from its world-leading experience in autologous cell processing resulting from marketed therapies that have been administered to over 6,000 cancer patients at Medinet's network of Contracted Medical Institutions since 1999.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

For more information, visit http://www.maxcyte.com.

About Medinet

Medinet is a world leading company in cell therapy supporting medical service providers in Japan. Through its service, Medinet provides medical institutions with advanced technologies and knowhow in: cell processing and culturing, qu
'"/>




Page: 1 2 3

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/1/2015)... Calif. , Sept. 1, 2015 ... Care Management (CCM) and Drug Adherence m Health ... help automate the process of non face-to-face monitoring ... "With this new release of our apps, doctors ... management services along with our ONCHIT certified Physician, ...
(Date:9/1/2015)... September 1, 2015 The ... the basis of sectors, products & services and ... coupled with the increasing demand of advanced drugs ... to propel the growth for bioinformatics market. The ... efficiently is known as bioinformatics. Decreasing cost of ...
(Date:9/1/2015)... -- In nur zwei Jahren nach dem Erreichen ... Group schnell weltweit 3.000 Mitarbeiter erreicht. Diese Steigerung ... Markt der injizierbaren Medikamente und das ... SHL wieder. Foto - http://photos.prnewswire.com/prnh/20150820/259886 ... Design und Herstellung automatischer Injektoren und Pen-Injektoren und ...
Breaking Medicine Technology:SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2
... 11, 2011 As part of its re-branding initiative, ... website www.xeridiem.com .  Winner of MD+DI,s 2011 Medical ... Supplies Xeridiem has been recognized as an industry leader ... invasive medical devices. For over 25 years, Xeridiem has ...
... Inc. (OTC: HEWA), a leading VIPPS-accredited, retail, mail-order ... have among the lowest total prices for four ... The study was conducted by 43,739 Consumer ... and speed.  "Our national study of prices for ...
Cached Medicine Technology:Consumer Reports Finds HealthWarehouse.com Has Lowest Total Price for Lipitor, Nexium, Plavix, and Singulair 2
(Date:9/1/2015)... Melbourne, Florida (PRWEB) , ... ... ... Association of Professional Background Screeners (NAPBS®) has announced that Edge Information ... audit conducted by the Background Screening Credentialing Council (BSCC). , “Achieving ...
(Date:9/1/2015)... Winston-Salem, NC (PRWEB) , ... September 01, 2015 , ... ... (Science, Technology, Engineering and Math) disciplines since its inception more than 35 years ago. ... and high-school students and their teachers - and, not just those intent on pursuing ...
(Date:9/1/2015)... ... ... Royal River Natural Foods, a locally-owned independent natural health store in Freeport, Maine, ... found that, among those who had a stroke, people who used multivitamins survived longer ... September 2015 issue of “Natural Insights for Well Being,” which Royal River Natural Foods ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection ... same mission – to raise awareness of the FSH Society and further FSHD research. ...
(Date:9/1/2015)... ... , ... SC&H Group, a leading audit, tax, and consulting firm, received multiple ... Best” firm in the U.S., as well as being ranked a Top 100 Accounting ... U.S., selected exclusively on performance in specific areas of financial and operational management. ...
Breaking Medicine News(10 mins):Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2
... Feb. 15, 2011 Researchers from Korea ... sedation (BPS) using propofol in combination with midazolam ... better patient cooperation, and similar adverse event profiles ... the first prospective study of BPS in direct ...
... NY) February 15, 2011 A new study led by ... February 15, 2011, Advance Online Publication, International Journal of ... effect on the purchasing behavior of teenagers or what parents ... information at the same rate as adults, however they respond ...
... BROOK, Ill. Breast cancer screening with MRI can ... undergone chest irradiation for other diseases, according to a ... edition of Radiology . Women who receive ... like Hodgkin,s lymphoma face a significantly greater risk of ...
... News) -- A mini exercise bike that can be used while ... workers and others with sedentary jobs, according to a new study. ... set up in front of most office chairs and used while ... overweight and 40 years old, on average. They spent at least ...
... the first book to examine the 300-year ancestry of deaf ... psychiatry at Boston University School of Medicine (BUSM) and his ... communicate are members of an ethnic group. The book, ... the lives and culture of the people who identify themselves ...
... (HealthDay News) -- Obesity may be associated with reduced risk ... in men, a new study suggests. Open-angle glaucoma is ... damage to the optic nerve. In the study, researchers ... and older, who took part in the Rotterdam Study and ...
Cached Medicine News:Health News:Study compares balanced propofol sedation with conventional sedation for therapeutic GI endoscopic procedures 2Health News:Study compares balanced propofol sedation with conventional sedation for therapeutic GI endoscopic procedures 3Health News:Study compares balanced propofol sedation with conventional sedation for therapeutic GI endoscopic procedures 4Health News:Calorie labeling has no effect on teenagers' or parents' food purchases 2Health News:Calorie labeling has no effect on teenagers' or parents' food purchases 3Health News:Breast cancer screening with MRI benefits women with radiation therapy history 2Health News:Boston University School of Medicine professor co-authors first book on deaf ethnicity 2Health News:Obesity Seems to Cut Women's Risk of Open-Angle Glaucoma 2
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: